Monograph
J05AF05 - Lamivudine |
Propably not porphyrinogenic |
PNP |
Side effects
Common adverse reactions of lamivudine that can be confused with an acute porphyric attack are nausea, vomiting, abdominal pain and diarrhoea. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Lamivudine is not metabolized by CYP450 enzymes, and is not an inducer or a mechanism-based inhibitor of CYP450 enzymes. No pharmacokinetic porphyrinogenic effects are suspected.
Chemical description
Nucleoside analogue
Therapeutic characteristics
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV-1 and hepatitis B. It is administered orally.
Metabolism and pharmacokinetics
Lamivudine is not a substrate, inhibitor or inducer of CYP450 enzymes (Johnson 1999, SPC).
The majority of lamivudine is eliminated unchanged through the kidney, and only 5 % is metabolized to trans-sulfoxide (Kumar 2010).
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Clinical pharmacokinetics of lamivudine.
Johnson MA, Moore KH, et al. Clin Pharmacokinet. 1999 Jan;36(1):41-66. |
|
| 2. |
Kumar PN, Patel P. Lamivudine for the treatment of HIV. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):105-14. |
20001611 |
| * | Summary of Product Characteristics | |
| 3. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Epivir).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024